A randomized trial to determine the impact of indacaterol/glycopyrronium on nighttime oxygenation and symptoms in patients with moderate-to-severe COPD: the DuoSleep study
Sverre Lehmann,1,2 Thomas Ringbæk,3 Anders Løkke,4 Ludger Grote,5 Jan Hedner,6 Eva Lindberg7 1Department of Thoracic Medicine, Norwegian Competence Center for Sleep Disorders, Haukeland University Hospital, Bergen, Norway; 2Section of Thoracic Medicine, Department of Clinical Sc...
Main Authors: | Lehmann S, Ringbæk T, Løkke A, Grote L, Hedner J, Lindberg E |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-01-01
|
Series: | International Journal of COPD |
Subjects: | |
Online Access: | https://www.dovepress.com/a-randomized-trial-to-determine-the-impact-of-indacaterolglycopyrroniu-peer-reviewed-article-COPD |
Similar Items
-
Cost-Effectiveness of Dual Bronchodilator Indacaterol/Glycopyrronium for COPD Treatment in China
by: Gong S, et al.
Published: (2021-02-01) -
Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide
by: Ridolo E, et al.
Published: (2019-01-01) -
Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial
by: Claus F. Vogelmeier, et al.
Published: (2017-07-01) -
Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study
by: Wedzicha JA, et al.
Published: (2017-01-01) -
Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD
by: Chan M, et al.
Published: (2018-04-01)